What were Johnson & Johnson's second-quarter sales and adjusted earnings per share, and how did they compare to Wall Street estimates?

Johnson & Johnson reported second-quarter sales of $25.31 billion, up 6.6% year-over-year and above the analyst average estimate of about $25.05 billion; adjusted earnings were $2.90 per share, up 4.7% year-over-year and exceeding analyst expectations of $2.85.

How did Tremfya and Darzalex perform in the second quarter, and what role do they play in J&J's pharmaceutical unit growth?

Tremfya sales rose 72.5% to $2 billion—well above LSEG estimates of $1.74 billion—and are increasingly critical in offsetting steep revenue declines from Stelara following patent expiration; Darzalex sales were $4.2 billion, roughly in line with analyst estimates, contributing to the pharmaceutical unit’s $16.38 billion in quarterly sales, which exceeded analyst estimates of $16.1 billion.

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

Jul 15, 2026

Johnson & Johnson beat Q2 sales and profit estimates, driven by strong growth in key drugs like Tremfya and Darzalex. It raised its full-year forecast despite challenges in its medical technology unit regarding heart pump sales.

reuters

2026-04-14

Johnson & Johnson First-Quarter Profit Beats Estimates Despite Stelara Sales Decline

2026-06-05

J&J Wins Lawsuit Alleging Talc Caused Three Women's Cancer

2026-07-15

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

FAQ